How I treat Philadelphia chromosome–like acute lymphoblastic leukemia in children, adolescents, and young adults
Blood · 2025
DOI: 10.1182/blood.2023023153 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Blood, 2025. Verfasst von Thai Hoa Tran und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine, Montréal, QC, Canada. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Philadelphia Chromosome. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) represents a high-risk B-lineage ALL subtype characterized by adverse clinical features and poor relapse-free survival despite risk–adapted multiagent chemotherapy regimens. The advent of next-generation sequencing has unraveled the diversity of kinase-activating genetic drivers in Ph-like ALL that are potentially amenable to personalized molecularly-targeted therapies. Based upon robust preclinical data and promising case series of clinical activity of tyrosine kinase inhibitor (TKI)–based treatment in adults and children with relevant genetic Ph-like ALL subtypes, several clinical trials have investigated the efficacy of JAK- or ABL-directed TKIs in cytokine receptor-like factor 2 (CRLF2)/JAK pathway-mutant or ABL-class Ph-like ALL, respectively. The final results of these trials are pending, and standard-of-care therapeutic approaches for patients with Ph-like ALL have yet to be defined. In this How I Treat perspective, we review recent literature to guide current evidence-based treatment recommendations via illustrative clinical vignettes of children, adolescents, and young adults with newly diagnosed or relapsed/refractory Ph-like ALL, and we further highlight open and soon-to-open trials investigating immunotherapy and TKIs specifically for this high-risk patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine, Montréal, QC, Canada.
- Department of Pediatrics, Faculty of Medicine, University of Montréal, Montréal, QC, Canada.
- Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA.
- Department of Pediatrics and Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
ORCID-Profile: Thai Hoa Tran, Sarah K Tasian
Förderung
- NCI NIH HHS
Zitieren
APA
Tran, T. H., & Tasian, S. K. (2025). How I treat Philadelphia chromosome–like acute lymphoblastic leukemia in children, adolescents, and young adults. Blood. https://doi.org/10.1182/blood.2023023153
Vancouver
Tran TH, Tasian SK. How I treat Philadelphia chromosome–like acute lymphoblastic leukemia in children, adolescents, and young adults. Blood. 2025. doi:10.1182/blood.2023023153
BibTeX
@article{Tran2025,
author = {Tran, Thai Hoa and Tasian, Sarah K},
title = {How I treat Philadelphia chromosome–like acute lymphoblastic leukemia in children, adolescents, and young adults},
journal = {Blood},
year = {2025},
doi = {10.1182/blood.2023023153}
}
EUVIMED